N-(2,2-Dimethylpropyl)-3,3-dimethyl-1-butanamine | 951160-87-5

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: N-(2,2-Dimethylpropyl)-3,3-dimethyl-1-butanamine
• 英文别名: N-(2,2-dimethylpropyl)-3,3-dimethylbutan-1-amine
• CAS: 951160-87-5
• 化学式: C₁₁H₂₅N
• 分子量: 171.32
• InChiKey: ARBNCHWIVFJVBY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  12
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  12
• 氢给体数：
  1
• 氢受体数：
  1

文献信息

• Macrocyclic Modulators of the Ghrelin Receptor
  申请人：Marsault Eric

  公开号：US20090221689A1

  公开（公告）日：2009-09-03

  The present invention provides novel conformationally-defined macrocyclic compounds that have been demonstrated to be selective modulators of the ghrelin receptor (growth hormone secretagogue receptor, GHS-R1a and subtypes, isoforms and variants thereof). Methods of synthesizing the novel compounds are also described herein. These compounds are useful as agonists of the ghrelin receptor and as medicaments for treatment and prevention of a range of medical conditions including, but not limited to, metabolic and/or endocrine disorders, gastrointestinal disorders, cardiovascular disorders, obesity and obesity-associated disorders, central nervous system disorders, genetic disorders, hyperproliferative disorders and inflammatory disorders.

  本发明提供了新型构象定义的大环化合物，已被证明是生长激素释放肽受体（GHS-R1a及其亚型，同工型和变异体）的选择性调节剂。本文还描述了合成新型化合物的方法。这些化合物可用作生长激素释放肽受体的激动剂，并作为治疗和预防一系列医疗状况的药物，包括但不限于代谢和/或内分泌紊乱，胃肠道疾病，心血管疾病，肥胖和肥胖相关疾病，中枢神经系统疾病，遗传性疾病，高增殖性疾病和炎症性疾病。
• TRIAZOLYL PYRIDYL BENZENESULFONAMIDES
  申请人：Charvat T. Trevor

  公开号：US20080039504A1

  公开（公告）日：2008-02-14

  Compounds are provided that act as potent antagonists of the CCR2 or CCR9 receptor. Animal testing demonstrates that these compounds are useful for treating inflammation, a hallmark disease for CCR2 and CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR2-mediated diseases, CCR9-mediated diseases, as controls in assays for the identification of CCR2 antagonists and as controls in assays for the identification of CCR9 antagonists.

  提供了化合物，作为CCR2或CCR9受体的有效拮抗剂。动物实验表明，这些化合物可用于治疗炎症，这是CCR2和CCR9的典型疾病。这些化合物通常是芳基磺酰胺衍生物，可用于制药组合物，治疗CCR2介导疾病和CCR9介导疾病的方法，作为CCR2拮抗剂鉴定的检测控制和作为CCR9拮抗剂鉴定的检测控制。
• Ophthalmic Compositions for Treating Ocular Hypertension
  申请人：Doherty James B.

  公开号：US20090062280A1

  公开（公告）日：2009-03-05

  This invention relates to the use of potent potassium channel blockers or a formulation thereof in the treatment of glaucoma and other conditions which leads to elevated intraocular pressure in the eye of a patient. This invention also relates to the use of such compounds to provide a neuroprotective effect to the eye of mammalian species, particularly humans.

  本发明涉及在治疗青光眼和其他导致患者眼内压升高的疾病中使用强效钾通道阻滞剂或其配方。本发明还涉及使用这些化合物在哺乳动物，特别是人类的眼中提供神经保护作用。
• Pesticidial Condensed-Ring Aryl Compounds
  申请人：Murata Tetsuya

  公开号：US20110071141A1

  公开（公告）日：2011-03-24

  Condensed-ring aryl compounds of formula (I) and use of the same as a agrochemical for controlling noxious organisms wherein (X) m Q, A, R 1 , (Y) n and the grouping —W 1 —W 2 —W 3 —W 4 — are as defined herein.

  公式（I）的紧缩环芳基化合物和将其用作农药，用于控制有害生物，其中（X）mQ，A，R1，（Y）n和基团—W1—W2—W3—W4—如本文所定义。
• Tetracycline Compounds
  申请人：Chen Chi-Li

  公开号：US20120135968A1

  公开（公告）日：2012-05-31

  The present invention is directed to a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. The variables for Structural Formula I are defined herein. Also described is a pharmaceutical composition comprising the compound of Structural Formula I and its therapeutic use.

  本发明涉及一种由结构式(I)表示的化合物或其药学上可接受的盐。结构式I的变量在此定义。同时还描述了包含结构式I化合物的药物组合物及其治疗用途。